MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.euo.2024.01.017

Медицинская библиотека · European urology oncology · 2024

Unlocking the Potential of Adequate Bacillus Calmette-Guérin Immunotherapy in Very-high-risk Non-muscle-invasive Bladder Carcinoma: A Multicenter Analysis of Oncological Outcomes and Risk Dynamics.

Subiela José Daniel, Krajewski Wojciech, González-Padilla Daniel A, Laszkiewicz Jan, Taborda Javier, Aumatell Júlia, Sanchez Encinas Miguel, Basile Giuseppe, Moschini Marco, Caño-Velasco Jorge, Lopez Perez Enrique, Del Olmo Durán Pedro, Gallioli Andrea, Tukiendorf Andrzej, D'Andrea David, Yuen-Chun Teoh Jeremy, Serna Céspedes Alejandra, Pichler Renate, Afferi Luca, Del Giudice Francesco, Gomez Rivas Juan, Albisinni Simone, Soria Francesco, Ploussard Guillaume, Mertens Laura S, Rajwa Paweł, Laukhtina Ekaterina, Pradere Benjamin, Tully Karl, Guerrero-Ramos Félix, Rodríguez-Faba Óscar, Alvarez-Maestro Mario, Dominguez-Escrig Jose Luis, Szydełko Tomasz, Gomez Dos Santos Victoria, Jiménez Cidre Miguel Ángel, Burgos Revilla Francisco Javier, European Association of Urology-Young Academic Urologists EAU-YAU: Urothelial Carcinoma Working Group

СтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

BACKGROUND

The European Association of Urology (EAU) recommends discussing upfront radical cystectomy for all patients with very high risk (VHR) non-muscle-invasive bladder carcinoma (NMIBC), but the role of bacillus Calmette-Guérin (BCG) treatment remains controversial.

OBJECTIVE

To analyze oncological outcomes in VHR NMIBC patients (EAU risk groups) treated with adequate BCG.

DESIGN, SETTING, AND

PARTICIPANTS

A multi-institutional retrospective study involving patients with VHR NMIBC who received adequate BCG therapy from 2007 to 2020 was conducted.

OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: A survival analysis estimated recurrence-free survival (RFS), progression-free survival (PFS), and the cumulative incidence of cancer-specific mortality (CSM) after accounting for other causes of mortality as competing risk events and of the overall mortality (OM). Conditional survival probabilities for 0-4 yr without events were computed. Cox regression assessed the predictors of oncological outcomes.

RESULTS AND LIMITATION: A total of 640 patients, with a median 47 (32-67) mo follow-up for event-free individuals, were analyzed. High-grade RFS and PFS at 5 yr were 53% (49-57%) and 78% (74-82%), respectively. The cumulative incidence of CSM and OM at 5 yr was 13% (10-16%) and 16% (13-19%), respectively. Conditional RFS, PFS, overall survival, and cancer-specific survival at 4 yr were 91%, 96%, 87%, and 94%, respectively. Cox regression identified tumor grade (hazard ratio [HR]: 1.54; 1.1-2) and size (HR: 1.3; 1.1-1.7) as RFS predictors. Tumor multiplicity predicted RFS (HR: 1.6; 1.3-2), PFS (HR: 2; 1.2-3.3), and CSM (HR: 2; 1.2-3.2), while age predicted OM (HR: 1.48; 1.1-2).

CONCLUSIONS

Patients with VHR NMIBC who receive adequate BCG therapy have a more favorable prognosis than predicted by EAU risk groups, especially among those with a sustained response, in whom continuing maintenance therapy emerges as a viable alternative to radical cystectomy.

PATIENT SUMMARY: Our research shows that a sustained response to bacillus Calmette-Guérin in patients can lead to favorable outcomes, serving as a viable alternative to cystectomy for select cases.

Для цитирования: Subiela José Daniel, Krajewski Wojciech, González-Padilla Daniel A, Laszkiewicz Jan, Taborda Javier, Aumatell Júlia, Sanchez Encinas Miguel, Basile Giuseppe, Moschini Marco, Caño-Velasco Jorge, Lopez Perez Enrique, Del Olmo Durán Pedro, Gallioli Andrea, Tukiendorf Andrzej, D'Andrea David, Yuen-Chun Teoh Jeremy, Serna Céspedes Alejandra, Pichler Renate, Afferi Luca, Del Giudice Francesco, Gomez Rivas Juan, Albisinni Simone, Soria Francesco, Ploussard Guillaume, Mertens Laura S, Rajwa Paweł, Laukhtina Ekaterina, Pradere Benjamin, Tully Karl, Guerrero-Ramos Félix, Rodríguez-Faba Óscar, Alvarez-Maestro Mario, Dominguez-Escrig Jose Luis, Szydełko Tomasz, Gomez Dos Santos Victoria, Jiménez Cidre Miguel Ángel, Burgos Revilla Francisco Javier, European Association of Urology-Young Academic Urologists EAU-YAU: Urothelial Carcinoma Working Group. Unlocking the Potential of Adequate Bacillus Calmette-Guérin Immunotherapy in Very-high-risk Non-muscle-invasive Bladder Carcinoma: A Multicenter Analysis of Oncological Outcomes and Risk Dynamics.. European urology oncology. 2024. DOI: 10.1016/j.euo.2024.01.017.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.